Survey data for Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon

This dataset consists of a single, openly-accessible OpenDocument Spreadsheet (<b>.ods</b>) file containing aggregated survey data on new cases of tuberculosis and Rifampicin resistance in Cameroon. Survey data were collected from all 248 tuberculosis (TB) diagnostic and treatment centres (DTC) managed by the National TB Programme (NTP), over a period of 6 weeks: 13th of March to 21st of April 2017.<br>Camerooon's network of DTCs diagnose virtually all of the country's TB cases. The related study investigated a 'notification gap' between the 175 actual Rifampicin resistant and/or multidrug resistant (RR/MDR-TB) patients and the WHO-estimated figure of 1,200 RR/MDR-TB cases. The study addresses whether this gap can be accounted for by testing new bacteriologically confirmed pulmonary TB cases (PTB+ NC).<br>All patients aged 15 years and above presenting at each DTC with symptoms compatible with pulmonary TB were asked according to NTCP guidelines to submit two sputum samples which were examined microscopically. A patient with a positive sputum for acid-fast bacilli (AFB) who had never been treated with anti-tuberculosis drugs for more than one month was considered a new pulmonary TB case with bacteriological confirmation (PTB+NC). Patients previously treated for TB as well as those with uncertain TB antecedents were excluded from the study.<br><br>The dataset contains data on the following variables for the 10 regions of Cameroon and the country in total:<br><b>Reg: </b>Region<b>Pop: </b>Population<b>NC: </b>New cases of PTB reported in this study<b>RR:</b> New cases of Rifampicin resistant PTB reported in this study<b>in_NC:</b> Incidence rate of new cases of PTB per 100,000 of overall population<br><b>in_RR:</b> Incidence rate of new cases of PTB with Rifampicin resistance per 100,000 of overall population<b>Sample: </b>Number of NC cases with positive Rifampicin resistance sample result<br><b>Prop_RR:</b> Proportion of new cases of PTB reported with Rifampicin resistance in this study<br><b>Conf_1 and </b><b>Conf_2: </b>Confidence intervals for estimated prevalence of MDR-TB in new bacteriologically-confirmed pulmonary TB cases<b>RR_2016</b><b>:</b> Rifampicin resistant and/or multidrug resistant (RR/MDR-TB) cases actually reported by DTCs in 2016<br><b>In_RR_2016: </b>Incidence rate of RR/MDR-TB per 100,000 of overall population as reported by DTCs in 2016<br><b>inTPM+-NC 2016: </b>Incidence rate of new cases of Rifampicin resistant PTB per 100,000 of overall population as reported by DTCs in 2016<br>The 10 regions of Cameroon are outlined in the related publication.

本数据集包含一份可公开获取的开放文档电子表格（OpenDocument Spreadsheet，.ods）文件，其中收录了喀麦隆地区结核病新增病例与利福平耐药性相关的汇总调研数据。
调研数据采集自喀麦隆国家结核病规划（National TB Programme, NTP）管理的全部248家结核病诊断与治疗中心（Diagnostic and Treatment Centre, DTC），采集周期为2017年3月13日至4月21日，共计6周。
喀麦隆的DTC网络几乎可诊断全国所有结核病病例。本相关研究针对175例实际确诊的利福平耐药/耐多药结核病（Rifampicin resistant and/or multidrug resistant, RR/MDR-TB）患者与世界卫生组织（WHO）估算的1200例RR/MDR-TB病例之间的“报告缺口”展开调查，旨在明确该缺口是否可通过检测新的细菌学确诊肺结核病例（PTB+ NC）进行解释。
根据国家结核病规划（NTCP）指南，所有年龄≥15岁、在各DTC就诊且伴有符合肺结核症状的患者需提交两份痰液样本，用于显微镜检查。从未接受抗结核药物治疗超过1个月的痰抗酸杆菌（acid-fast bacilli, AFB）阳性患者，被认定为细菌学确诊的新增肺结核病例（PTB+ NC）。既往接受过结核病治疗或结核病病史不明的患者被排除出本研究。

本数据集涵盖喀麦隆10个地区及全国层面的以下变量：
Reg：地区
Pop：人口总数
NC：本研究报告的新增肺结核病例数
RR：本研究报告的利福平耐药新增肺结核病例数
in_NC：每10万总人口中新增肺结核病例的发病率
in_RR：每10万总人口中利福平耐药新增肺结核病例的发病率
Sample：利福平耐药检测结果呈阳性的NC病例数
Prop_RR：本研究报告的利福平耐药新增肺结核病例占比
Conf_1与Conf_2：细菌学确诊新增肺结核病例中耐多药结核病估算患病率的置信区间
RR_2016：2016年各DTC实际报告的利福平耐药/耐多药结核病病例数
In_RR_2016：2016年各DTC报告的每10万总人口中RR/MDR-TB发病率
inTPM+-NC 2016：2016年各DTC报告的每10万总人口中利福平耐药新增肺结核病例发病率
喀麦隆的10个地区划分详见相关发表文献。